FTC K-Dur Suit Would Allow Andrx Generic Launch; FDA Could Act First
Executive Summary
Andrx believes it may be able to launch a generic version of Schering-Plough's K-Dur during the second half of the year regardless of the outcome of the Federal Trade Commission's administrative action over patent settlements involving K-Dur.
You may also be interested in...
FTC K-Dur Case Incorrectly Defines Market, Judge Says In Ruling For Schering
Merck-Medco's decision not to separately list Schering-Plough's K-Dur on its formulary is evidence that the drug is therapeutically substitutable and competes with other versions of potassium chloride, an administrative law judge said
FTC K-Dur Case Incorrectly Defines Market, Judge Says In Ruling For Schering
Merck-Medco's decision not to separately list Schering-Plough's K-Dur on its formulary is evidence that the drug is therapeutically substitutable and competes with other versions of potassium chloride, an administrative law judge said
Biovail Says Tiazac Andrx Settlement “Satisfies” FTC; Patent Remains Listed
Biovail's Tiazac patent litigation settlement with Andrx satisfies the Federal Trade Commission's concerns regarding late-listed Tiazac patents, Biovail says